Diabetes Care Devices and Drugs Market (2017-2022)
Diabetes is one of the largest global health emergencies of the 21st century. Each year more and more people live with this condition, which can result in life-changing complications. In addition to the 415 million adults who are estimated to have diabetes globally in 2015, there are 318 million adults with impaired glucose tolerance, which puts them at high risk of developing the chronic disease in the future. The incidence & prevalence of diabetes is growing with rising obesity rates, changing lifestyle and dietary habits, and growing ageing population. Therefore, given the huge numbers of diabetics worldwide and the huge financial implications associated with diabetes and related further health complications, there is a substantial market potential in the global diabetes care devices & drugs market in the next 5-10 years. The global diabetes care devices & drugs market are expected to grow at a CAGR of 5.2% from 2017 to 2022 to reach $85,591.2 million by 2022.
- Published
- Oct 2017
- Pages
- 217
- Format
- PDF + Excel
- Report ID
- MR-122
- Base year
- 2016
- 2022 · FORECAST
- $85.59B
- 2022
- $85.59B
- CAGR 2017–2022
- 5.2%
2016 baseline · 2017–2022 forecast at 5.2% CAGR · hover a bar for the value
Report summary
| Particulars | Details |
|---|---|
| Base Year | 2016 |
| Estimated Year | 2017 |
| Forecast Period | 2017–2022 |
| Market Size (2022) | USD 85.59 billion |
| CAGR (2017–2022) | 5.2% |
| Format | PDF, Excel & Cloud Portal · 217 pages |
| Segments Covered | By Type of Device: Continuous Blood Glucose Monitoring Devices, Test Strips, Lancets, Self-monitoring Devices, Haemoglobin A1c Testing Kits, Insulin Syringes, Insulin Pens, Insulin Pumps, Insulin Jet Injectors · By Drug: Insulin, Oral Hypoglycaemic Agents, Non-Insulin Injectable |
| Countries Covered | North America (Canada), Europe (Germany, France, U.K., Italy, Spain, Rest of Europe), Asia-Pacific (Japan, China, India, Rest of Asia-Pacific) |
Report overview
Segments covered: type of device, drug. Regions: North America, Europe, Asia-Pacific.
Following a comprehensive research on the global diabetes care devices & drugs market and an in-depth analysis of the market scenario, the report carries out an impact analysis of the key industry drivers, restraints, and opportunities, listed in the market insights segment. Increasing incidence & prevalence of diabetes, technological advancements, rise in obesity, and increasing sedentary lifestyle and improper diet are the key market drivers covered in the report which will support the industry growth in the forecast period. However, high cost associated with diagnosis and treatment, reimbursement issues, and lack of awareness are the major pain points, restraining the adoption of the diabetes care devices & drugs market in various countries across the globe.
The report further gives an extensive outlook on the multifarious segments and sub-segments in both diabetes care devices and drugs market. The diabetes care devices market further talks about the trends impacting the growth of diabetes monitoring devices and insulin delivery devices including their sub-segments. The diabetes care drugs market in detail speaks about insulin, oral-hypoglycemic drugs, and non-insulin injectable drugs.
An exhaustive analysis of the geographical scenario of the industry for the five major geographies: North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa is included in the geographical analysis section. These regions are further analyzed at a country level with the detailed qualitative and quantitative analysis. The geographical analysis provides detailed insights on the key trends of the industry in the listed regions & countries, identifying the disease incidence & prevalence, demographic & economic impact, government & private investments, and regulatory scenario. The report identifies North America to be the largest market, followed by Europe, Asia-Pacific, Latin America and Middle East & Africa. The geographical analysis section also comments on the key market players shaping the growth of the industry in the respective countries.
The report also includes the competitive landscape based on extensive assessment of the key strategic developments adopted by leading market participants in the industry over the past 3 years (2015-2017). The study has also incorporated the market share analysis of leading players in each of the diabetes care devices and drugs market, and detailed profiles of 15 top market players across the value chain of the industry, including detailed financial performance, product offerings, and strategic growth initiatives of each player.
The key players operating in the global diabetes care devices & drugs market are Novo Nordisk A/S (Denmark), Ypsomed AG (Switzerland), Abbott Laboratories (U.S.), Ascensia Diabetes Care Holdings AG (Switzerland), Eli Lilly and Company (U.S.), Hoffmann-La Roche Ltd.(Switzerland), Johnson & Johnson (U.S.), Medtronic PLC (Ireland), Becton, Dickinson and Company (U.S.), Terumo Corporation (Japan), Sanofi S.A. (France), Merck & Co., Inc.(U.S.), Novartis AG (Switzerland), AstraZeneca PLC (U.K.), and Boehringer Ingelheim GmbH (Germany).
What factors contribute to the infrequent usage of insulin delivery devices in healthcare sector?
Conversely, which geographic segment is expected to experience the fastest growth for on insulin delivery devices.
Table of contents
10 chapters · 102 sections · 217 pages · click to expandGeographic analysis
North America
Recent partnerships, agreements, and expansions have taken place in the diabetes care devices & drugs market space. The North American diabetes care devices & drugs market favors both larger and local manufacturers that compete in multiple segments
Cite this report
Meticulous Research. (2017). Diabetes Care Devices and Drugs Market - Global Opportunity Analysis and Industry Forecast (2017-2022) (Report No. MR-122). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/diabetes-care-devices-drugs-market-3305